Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, 2025. The Zacks Consensus Estimate for fourth-quarter revenues is pegged at ...

The fight for dominance between Regeneron and Bayer’s big blockbuster eye drug Eylea and Roche’s rival Vabysmo is playing out ...

Bayer UK launches new CanesMeno Educational Hub and product range to transform menopause support: Leverkusen Friday, January ...

Bayer Thai Co., Ltd. has been honoured with the 2025 Thailand Best Employer Brand Award, a prestigious recognition presented ...

Learn more about whether Ionis Pharmaceuticals, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Similiar legislation died last year after getting House approval.

An avalanche of lawsuits filed against Bayer in Missouri is pitting the chemical maker against trial attorneys and cancer patients.

Berenberg Bank analyst Sebastian Bray maintained a Hold rating on Bayer (0P6S – Research Report) today and set a price target of €22.00. The ...

The settlement with 15 states will resolve lawsuits alleging the drug OxyContin caused the opioid epidemic. ( Reuters) Bayer ...

Kepler Capital analyst Christian Faitz maintained a Hold rating on Bayer (0P6S – Research Report) on January 21 and set a price target of ...

As leaders gather for the World Economic Forum Annual Meeting 2025 in Davos, Leaps by Bayer, the impact investing arm of Bayer ... society's need for solutions to climate change, strained healthcare ...

Global healthcare spending is $9.8 trillion; the U.S. accounts for about $4.9 trillion. Investors should evaluate the growth prospects, financial strength, valuation, and dividends of healthcare ...